Home » Stocks » Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. (PLX)

Stock Price: $3.71 USD 0.17 (4.80%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 120.36M
Revenue (ttm) 64.62M
Net Income (ttm) -5.75M
Shares Out 32.44M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $3.71
Previous Close $3.54
Change ($) 0.17
Change (%) 4.80%
Day's Open 3.61
Day's Range 3.52 - 3.80
Day's Volume 189,155
52-Week Range 1.70 - 4.87

More Stats

Market Cap 120.36M
Enterprise Value 147.97M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.44M
Float 16.94M
EPS (basic) -0.16
EPS (diluted) -0.33
FCF / Share -0.70
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 350,382
Short Ratio 2.57
Short % of Float 1.09%
Beta 2.94
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.86
PB Ratio n/a
Revenue 64.62M
Operating Income 3.11M
Net Income -5.75M
Free Cash Flow -22.56M
Net Cash -27.60M
Net Cash / Share -0.85
Gross Margin 67.78%
Operating Margin 4.81%
Profit Margin -8.90%
FCF Margin -34.91%
ROA 3.06%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.75*
(162.80% upside)
Low
8.50
Current: $3.71
High
11.00
Target: 9.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue54.6934.2421.089.204.363.52-34.422.9711.24
Revenue Growth59.73%62.44%129.13%110.79%23.87%--1059.84%-73.6%-
Gross Profit43.8024.945.850.803.632.89-26.281.446.86
Operating Income-10.72-19.31-34.52-33.16-23.67-28.56-34.06-12.17-36.53-29.97
Net Income-18.28-26.46-83.44-29.3758.04-29.94-27.79-11.62-36.53-29.00
Shares Outstanding14.8414.7113.1110.149.499.299.249.088.468.10
Earnings Per Share-1.23-1.80-6.37-2.906.10-3.20-3.00-1.30-4.30-3.60
Operating Cash Flow-19.36-7.74-9.99-32.10-24.28-29.28-30.650.64-23.57-38.46
Capital Expenditures-0.63-0.69-0.97-0.83-0.46-0.77-1.89-2.07-5.70-7.86
Free Cash Flow-19.99-8.43-10.96-32.93-24.75-30.06-32.54-1.43-29.27-46.32
Cash & Equivalents17.7937.8151.1663.2876.3754.7786.4052.0427.0035.90
Total Debt60.9347.9752.1973.2272.1067.3567.05---
Net Cash / Debt-43.13-10.16-1.03-9.934.28-12.5819.3552.0427.0035.90
Assets45.3961.1372.2182.2597.2578.3611378.7351.8164.73
Liabilities11611410292.2086.3813414082.0877.8876.05
Book Value-70.32-52.88-29.46-9.9610.87-55.60-26.95-3.36-26.08-11.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Protalix BioTherapeutics, Inc.
Country Israel
Employees 196
CEO Dror Bashan

Stock Information

Ticker Symbol PLX
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: PLX
IPO Date May 15, 1998

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.